Brett Monia, Ionis Pharmaceuticals CEO
July 11, 2022 10:42 AM EDT
Deals
R&D

Io­n­is hands off an an­ti­sense drug for kid­ney dis­ease, giv­ing all rights to Roche

Paul Schloesser

Associate Editor

Io­n­is is hand­ing Roche a drug on the cusp of Phase III.

Io­n­is an­nounced ear­ly Mon­day that Roche is in-li­cens­ing and ad­vanc­ing the an­ti­sense drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times